Developing a High-throughput Platform for Drug Toxicity Screening
ISEF · 2017 Translational Medical Science Fourth Award
Overview
Cardiotoxicity accounts for a third of withdrawn pharmaceuticals, hence evaluating drug compounds for cardiotoxicity is essential in drug development. However, primary human cardiomyocytes are not easily obtained and substantial differences between human and animal genomes have resulted in numerous tests failing to correlate drug toxicity when advancing from animal studies to human clinical trials, wasting precious resources. Currently used in vitro systems such as patch clamping and impedance assays are costly or low-throughput. Hence this study aimed to develop a novel high-throughput human model for cardiotoxicity studies using human induced pluripotent stem cell (iPSC)-derived cardiomyocytes. Human iPSCs were differentiated into highly enriched cardiomyocytes which exhibited spontaneous contraction and expressed cardiac marker proteins such as Actinin and cTnT. Functional cardiomyocytes were plated down in 384-well plates and treated with various drugs of known clinical cardiac risk, and their functional endpoints were tracked automatically. The platform developed for toxicity testing yielded results which matched clinical trials, with the cardiomyocytes displaying concentration-dependent response in beating frequency and contraction amplitude for a range of drugs. Several drugs known to cause torsades de pointes arrhythmia, including Cisapride, Dofetilide and Quinidine, resulted in a significant decrease in cardiomyocyte contraction speed and amplitude at low concentrations, suggesting that the assay can accurately predict drug-induced toxicity and detect functional abnormalities. Furthermore, the platform developed was low-cost and allowed for high-throughput screening of multiple compounds, hence making it a sensitive and efficient platform of clinical relevance.
Awards (3)
- Fourth Award of $500 $500
- National Anti-Vivisection Society: First Award of $5,000 $5,000
- NASA: Second Award of $750 $750
Competition history
- ISEF 2017
Resources
Related projects
ISEF · 2025
MicroHeart: A Novel, Structurally Accurate, Physiologically Relevant, and Scalable Heart-on-a-Chip Platform
ISEF · 2014
Induced Pluripotent Stem Cell-Derived Cardiomyocytes as a Model for Ischemia Reperfusion Injury
ISEF · 2015
Optimizing the Culture Conditions for Differentiation of Human induced Pluripotent Stem Cells into Cardiac Cells
ISEF · 2015
Diabetic Stem Cell Derived Cardiomyocytes in Disease Modeling and Therapeutic Discovery
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair